Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data

Executive Summary

A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs
Advertisement

Related Content

FDA Panel Looks Beyond Xarelto’s Missing Data Problems To Broader Reforms
Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning
Cardiovascular Outcomes Trials Increasingly Complicated By Missing Data
Cardiovascular Outcomes Trials Increasingly Complicated By Missing Data
Cardiovascular Outcomes Trials Increasingly Complicated By Missing Data
Prevention And Treatment Of Missing Clinical Trial Data
Cymbalta Advisory Committee Review In Chronic Pain Now Set For August
Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
Patient Dropouts, Other “Missing Data” To Be Addressed In FDA Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS052532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel